Thromboprophylaxis in the COVID-19 surgical patient

Abstract

Clotting disorders have been one of the problems that clinicians have dealt with in the course of learning about this new disease. There is very little evidence and limited recommendations by scientific societies on the management of thromboprophylaxis in the COVID-19 surgical patient, in addition to the fact that the effects of this pathology on surgical injury are unknown. The thrombotic risk assessment for the COVID-19 surgical patient is unprecedented in this regard. Some predictors and risk factors for thrombosis have been systematically reported as prognostic markers, including elevation of D-dimer, fibrinogen, IL6, serum ferritin, prolongation of clotting times, detection of antiphospholipid antibodies and other independent factors that contribute to measure severity. of COVID-19 such as lactate dehydrogenase and marked lymphopenia. The foregoing predictors and risk factors for thrombosis for COVID-19 disease have been adapted adjusted to the categories present on the Caprini scale in order of increasing complexity and in relation to morbidity and mortality. In this sense, the choice of the measure or measures that each patient requires will depend on their particular risk of developing venous thromboembolic disease against the anticipated risk of surgical bleeding complications from the surgery to which they will be subjected, allowing the identification of patients likely to develop complications. through the modified Caprini scoring system and you see guide and establish optimal thromboprophylaxis strategies.